NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th
Rare genetic diseases collectively affect hundreds of millions of people worldwide
The next generation of gene silencing technology
NeuBase has developed a modular antisense peptide nucleic acid (PNA) platform with the capability to address rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase has improved gene silencing therapies to include the advantages of synthetic approaches with the precision of antisense technologies.
Technology
The advantages of the NeuBase PATrOL™ platform enable the company to cohesively develop therapies for a wide range of rare genetic diseases, including repeat expansion disorders, dominant and recessive genetic disorders and cancers driven by specific oncogenic mutations.
NeuBase is first addressing Huntington’s disease and myotonic dystrophy.
The NeuBase technology has several advantages over traditional ASOs
Sd
Scalable & Modular Development
Pre-organized peptide backbone and toolkit of engineered nuclear bases allow drugs to be quickly snapped together for many targets
Ts
Targeting Secondary RNA Structures
Higher specificity for mutant over wild type transcript, allowing for fewer off-target effects and more effective deactivation of disease-related mRNA
Sa
Systemic Administration
Ability to cross the blood brain barrier and disseminate broadly, allowing for systemic administration in neurological indications
Ni
No Immune Response
Do not cause an immune response when systemically administered, enabling us to develop solutions for pre-symptomatic individuals who are gene positive
News & Views
NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019
NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today
NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board
NeuBase Therapeutics Hosting Key Opinion Leader Meeting on Huntington's Disease and PATrOL™-Enabled Therapy on September 16th
PITTSBURGH, Sept. 09, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced that it will host a Key Opinion Leader (KOL) meeting on Huntington's disease and NeuBase’s peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform on Monday, September 16, 2019 in New York City.
NeuBase Therapeutics Reports Financial Results for the Fiscal Third Quarter of 2019
Completed two financings in July 2019 totaling approximately $14 million in gross proceeds with participation from institutional investors including Greenlight Capital
NeuBase Therapeutics to Ring the NASDAQ Closing Bell Today
PITTSBURGH, Aug. 07, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” and the “Company”), a biotechnology company developing next generation antisense therapies to address genetic diseases, announced today that its chairman and chief executive officer, Dietrich A. Stephan, Ph.D., will be joined by other members of the management team to ring the NASDAQ closing bell today, August 7, 2019, to celebrate the Company’s recent listing on the NASDAQ.
NeuBase Therapeutics Announces Addition of Industry Pioneer Dr. Samuel Broder and World-Renowned Geneticist Dr. George Church to Scientific Advisory Board
PITTSBURGH, July 30, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address genetic diseases, today announced the addition of Samuel Broder, M.D, Ph.D. and George Church, Ph.D. to its scientific advisory board (SAB), bringing additional expertise in genetics, genomics, and oncology to a team already recognized for leadership in neurology, genomics and therapeutic development. The SAB will work closely with the NeuBase management team as the Company advances its next-generation gene regulating therapies through development, first in genetic diseases such as the repeat expansion disorders Huntington’s disease and myotonic dystrophy, as well as oncology, and then more broadly.